Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disease primarily affecting the cerebellum. Very little is known about the molecular mechanisms underlying the disease and, to date, no cure or treatment is available. We have successfully generated bona fide induced pluripotent stem cell (iPSC) lines of SCA2 patients in order to study a disease-specific phenotype. Here, we demonstrate the gene correction of the iPSC line H196 clone 7 where we have exchanged the expanded CAG repeat of the ATXN2 gene with the normal length found in healthy alleles. This gene corrected cell line will provide the ideal control to model SCA2 by iPSC technology.
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Resource details
An induced pluripoten stem cell (iPSC) line had been generated from human skin fibroblasts of a male, symptomatic 52-year-old spinocerebellar type 2 (SCA2) patient (anonymized as H196) using episomal vectors carrying transcripts for human OCT4, SOX2, KLF4, L-MYC, LIN28, and small hairpin RNA for TP53 (Okita et al. 2011 ). This cell line, H196 clone (c) 7, has been described as a bona fide iPSC line with a normal karyotype (Marthaler et al., submitted to Stem Cell Research) .
We have generated a gene-corrected clone of H196 c7 using the CRISPRs/Cas9 system (Ran et al. 2013) , where the expanded 36 CAG region in the ATXN2 gene has been replaced with a wildtype 22 CAG repeat (Fig. 1A) . Successful exchange was validated by sequencing (Fig.  1B) . We have furthermore confirmed that the DNA sequence stayed intact and no frameshift or other mutation had been introduced into the gene edited site, by analyzing the region around the CRISPR cutting site (nucleotide 119-141 in Fig. 1A ).
Subsequently, we confirmed that the gene corrected clone of H196 c7, termed H196 c7 GC, remained truly pluripotent. This was demonstrated by expression of key pluripotency markers on RNA, as well as protein level ( Fig. 1C and D ) . Additionally, H196 c7 GC retained the potential to differentiate into cell types of the three germ layers upon embryoid body formation (Fig. 1E ). More importantly, no genetic chromosomal aberrations were introduced by the gene editing process and the cells still exhibit a normal karyotype (Fig. 1F) . In summary, we have generated an isogenic, gene-corrected iPSC line of an existing SCA2 iPSC line. Together with two more SCA2 patient-derived iPSC lines and their corresponding isogenic, genecorrected controls (Marthaler et al., submitted to Stem Cell Research), they will serve as an ideal study tool for in vitro disease modeling of SCA2.
Materials and methods

CRISPR design
Isogenic gene-corrected controls were obtained using the CRISPRs/Cas9 system in combination with a homologous construct in the pEasy Flox II vector. CRISPRs targeting each site of the CAG repeat of the ATXN2 locus were designed at http://crispr.mit.edu/. The CRISPRs were generated following the protocol from Ran et al. (Ran et al. 2013 ) in a single plasmid containing both sgRNA and the Cas9 (Addgene plasmid ID 48139).
Nucleofection
iPSCs growing on dishes coated with matrigel (Corning Bioscience) in E8 medium (Gibco) were detached using Accutase (Gibco). 10 6 cells were co-nucleofected with 2 μg of each CRISPR/ Cas9 plasmid and 1 μg of the resistance marker using the Amaxa 4D Nucleofector (program CA167) and P3 Primary Cell Kit according to the manufacturer's instructions (Lonza). iPSCs were subsequently transferred back to a matrigel-coated dish in E8 medium supplemented with 1 mM ROCK inhibitor (Sigma). 24 h post nucleofection, cells were subjected to neomycin selection and allowed to recover for a week. Resistant colonies were then picked and expanded for genotyping.
Genotyping
DNA for genotyping was extracted using the FlexiGene Kit (Qiagen). PCR genotyping was performed using TEMPase Hot Start DNA Polymerase (Ampliqon) according to the manufacturer's instructions at an annealing temperature of 58°C. The following primers were designed 300 base pairs up-and downstream of the CRISPR cutting site to ensure detection of insertion at homologous site: SCA2 long1 forward 5′-CAGA CCCGCCTTGAGGAAG-3′ and SCA2 long1 reverse 5′-GAGGAGACCGAG GACGAGG-3′. Clones where the expanded SCA2 allele was successfully replaced with the ATXN2 wildtype construct were subjected to sequencing to exclude introduction of frameshifts or other mutations.
Sequencing
Sanger sequencing of a 300 base pair region around the CAG repeat region of the ATXN2 gene was carried out in an ABI PRISM 310 Genetic Analyzer using the primers SCA2 seq2 forward 5′-CTTGGTCTCGGCGG GC-3′ and SCA2 seq2 reverse 5′-GAGGAGACCGAGGACGAGG-3′.
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qRT-PCR)
RNA was extracted using RNeasy Mini (QIAGEN) and cDNA synthesis was performed using Revert Aid First Strand cDNA synthesis kit (Thermo Scientific) according to the manufacturers' protocols. qRT-PCR was carried out using LightCycler 480 SYBR Green I Master (Roche). Data was plotted using the delta delta Ct algorithm, 2 (−ΔΔCt) . The following primers were used:
3.6. Immunocytochemistry
Immunocytochemistry was performed as previously described (Marthaler et al. 2013) . The following primary antibodies were used: Anti-OCT4 (Santa Cruz, sc 8628); anti-NANOG (Peprotech, 500P236); anti-TRA1-60 (BioLegend, 330,602); anti-SSEA4 (BioLegend, 330,402); anti-TUBB3 (Millipore, MAB1637); anti-SMA (Dako, M0851), anti-AFP (Dako, A0008); all 1:500. Secondary antibodies used were: Alexa Fluor 488 donkey anti-rabbit (A21206), donkey anti-goat (A11055), and goat anti-mouse (A11017), all 1:2000 (Invitrogen).
Embryoid body differentiation
iPSCs growing in E8 medium (Gibco) on matrigel (Corning Bioscience) were dissociated with EDTA (Gibco) and allowed to form aggregates in none-coated cell culture dishes. On day 3, aggregates were transferred to matrigel-coated dishes and medium was switched to differentiation medium: DMEM/F12 containing 20% FBS, L-glutamine, and non-essential amino acids (all Gibco) for meso-and endoderm induction, or DMEM/F12 containing 50% neurobasal medium, B27, N2, and L-glutamine (all Gibco) for ectoderm induction. Cells were fixed for immunocytochemistry on day 14.
Verification and authentication
An intact genome was demonstrated by karyotyping using Gbanding (Fig. 1F) . Analysis was performed at the Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. 
